{"id":22506,"date":"2025-05-08T11:00:38","date_gmt":"2025-05-08T04:00:38","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=22506"},"modified":"2025-05-08T11:00:38","modified_gmt":"2025-05-08T04:00:38","slug":"brii-bio-presents-late-breaking-data-from-its-ongoing-phase-2-ensure-study-at-easl-congress-2025-suggesting-brii-179s-role-in-advancing-higher-hbsag-loss","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=22506","title":{"rendered":"Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179&#8217;s Role in Advancing Higher HBsAg Loss"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1690538\/Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li> <i>End of treatment (EOT) data from Cohort 4 of the\u00a0ENSURE\u00a0study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 <\/i> <i>na\u00efve participants<\/i> <i>, strengthening the case for a novel\u00a0enrichment strategy, utilizing\u00a0BRII-179 to\u00a0identify\u00a0and prime patients for improved functional cure outcomes<\/i> <\/li>\n<li> <i>24 Week follow-up results from Cohorts 1-3 of the ENSURE study demonstrated sustained off-treatment benefits of elebsiran + PEG-IFN\u03b1 combination<\/i> <i>therapy vs PEG-IFN\u03b1 alone<\/i> <\/li>\n<\/ul>\n<p> <span class=\"legendSpanClass\">DURHAM, N.C. and BEIJING<\/span>, <span class=\"legendSpanClass\">May 8, 2025<\/span> \/PRNewswire\/ &#8212; <a href=\"http:\/\/www.briibio.com\/\" target=\"_blank\" rel=\"nofollow\">Brii Biosciences Limited<\/a> (&#8220;Brii Bio&#8221; or the &#8220;Company&#8221;, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced data from its ongoing Phase 2 ENSURE study\u00a0as late-breaking posters at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, the Netherlands.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>ENSURE (NCT05970289) is a multicenter, open-label\u00a0Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to the combination treatment with pegylated interferon alpha (PEG-IFN\u03b1) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU\/mL.<\/p>\n<p>Cohort 4 enrolled participants who completed 9 doses of BRII-179, a recombinant protein-based therapeutic vaccine,\u00a0in combination with elebsiran in a previous APAC study BRII-179-835-001 (NCT04749368) to receive elebsiran and PEG-IFN\u03b1 combination treatment. These participants were grouped based on their anti-HBs response induced by prior BRII-179 treatment: those with peak anti-HBs titers \u2265 10 IU\/L are defined as anti-HBs responders, and those with peak anti-HBs titers &lt; 10 IU\/L as non-responders. The design of Cohort 4 as part of this study was based on the insight that BRII-179 could differentiate between immune responders and non-responders, offering the potential to predict future response to therapy.<\/p>\n<p>Interim\u00a0data\u00a0from\u00a0Cohort 4 showed that anti-HBs responders achieved a substantially higher rate of HBsAg seroclearance than non-responders.\u00a0At EOT (Week 48), 61% (11\/18) of anti-HBs responders achieved HBsAg seroclearance, compared to 10% (1\/10) of non-responders. Among the 11 anti-HBs responders who achieved HBsAg loss, 91% (10\/11) had anti-HBs titers \u2265 100 IU\/L at EOT.<\/p>\n<p>Of note, BRII-179 experienced participants in Cohort 4 achieved HBsAg loss faster than BRII-179 na\u00efve\u00a0participants in Cohort 2 and 3. 83% (10\/12) of HBsAg loss in BRII-179 experienced participants occurred by Week 24, compared to 55% (6\/11) in BRII-179 na\u00efve participants. These findings suggest rapid HBsAg seroclearance in subjects with higher anti-HBs titers may translate into durable HBsAg loss and the potential to evaluate shorter treatment durations of PEG-IFN\u03b1.<\/p>\n<p>Additional data from Cohorts 1-3 of the ENSURE study showed the combination therapy of elebsiran either 100 mg or 200 mg and PEG-IFN\u03b1 resulted in higher HBsAg loss rate at 24 weeks post EOT compared to PEG-IFN\u03b1 alone, supporting the additive benefit of siRNA.<\/p>\n<p>&#8220;The data from Cohort 4 of the ENSURE study are encouraging. We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in\u00a0achieving\u00a0a higher HBsAg seroclearance rate,&#8221; said David Margolis, MD, Chief Medical Officer of Brii Bio. &#8220;With BRII-179, we may identify patients with less impaired intrinsic immunity and further prime their immune response. This approach may provide more durable HBsAg loss and potentially shorter treatment duration of PEG-IFN\u03b1. We are moving full speed ahead with our clinical efforts to deliver a meaningful option to the chronic hepatitis B patients long left waiting.&#8221;<\/p>\n<p> <b>Abstract Number:\u00a0<\/b>LB25123\/ LBP-018<\/p>\n<p> <b>Title:\u00a0<\/b>Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved faster and higher rate of hepatitis B virus surface antigen seroclearance on elebsiran plus pegylated interferon-alfa: end of treatment data from ENSURE study<\/p>\n<p> <b>Presenter:<\/b>\u00a0Grace Lai-Hung Wong, MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine), Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics\u00a0in Hong Kong SAR, China<\/p>\n<ul type=\"disc\">\n<li>A total of 28 participants with baseline\u00a0HBsAg &gt; 100 and \u2264 3000 IU\/mL were analyzed. 18 and 10 participants had peak anti-HBs titer \u2265 10 IU\/L (defined as anti-HBs responders) and &lt; 10 IU\/L (defined as non-responders) induced by BRII-179 in the previous study, respectively.<\/li>\n<li>Median [range]\u00a0HBsAg at the time of initiating elebsiran + PEG-IFN\u03b1 was numerically higher in anti-HBs responders (539.4 [106.7-2165.0] IU\/mL) than in non-responders (219.3 [106.7-671.5] IU\/mL). At EOT (Week 48), 61% (11\/18) of anti-HBs responders achieved HBsAg seroclearance, compared to 10% (1\/10) of non-responders.<\/li>\n<li>Among the\u00a0anti-HBs responders who lost HBsAg, 91% (10\/11) had anti-HBs titers \u2265 100 IU\/L at EOT.<\/li>\n<li>BRII-179 experienced participants achieved\u00a0HBsAg loss faster than BRII-179 na\u00efve participants, with 83% (10\/12) of HBsAg loss occurring by Week 24 (vs 55% [6\/11] in BRII-179 na\u00efve participants).<\/li>\n<li>Elebsiran + PEG-IFN\u03b1 was generally safe and tolerated in BRII-179 experienced participants.<\/li>\n<\/ul>\n<p> <b>Abstract Number:\u00a0<\/b>LB25115\/ LBP-016<br \/><b>Title: <\/b>Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study<br \/><b>Presenter:<\/b>\u00a0David Margolis, MD, MPH, Chief Medical Officer of Brii Biosciences<\/p>\n<ul type=\"disc\">\n<li>At Week 72 (24 weeks post\u00a0EOT), higher HBsAg loss rate was observed in participants on combination therapy of either elebsiran 200mg or 100 mg and PEG-IFN\u03b1 compared to PEG-IFN\u03b1 alone (21.1% [4\/19] or 33.3% [6\/18] vs 5.6% [1\/18]). \u00a0All the 11 participants with HBsAg loss had baseline HBsAg &lt; 1500 IU\/mL.<\/li>\n<li>Incidence of treatment emergent adverse events (TEAEs) was comparable between combination therapy cohorts and PEG-IFN\u03b1 alone cohort. Most TEAEs were consistent with known side effects of PEG-IFN\u03b1.<\/li>\n<\/ul>\n<p>As part of Brii Bio&#8217;s unique approach to developing a functional cure for HBV, the Company and its partners are actively progressing multiple combination studies with our differentiated portfolio, including\u00a0BRII-179 being evaluated in multiple combination studies with elebsiran led by Brii Bio; elebsiran being evaluated in combination with PEG-IFN\u03b1 in studies led by Brii Bio;\u00a0and tobevibart, an investigational broadly neutralizing monoclonal antibody targeting HBV, being evaluated in multiple Phase 2 and 3 tobevibart and elebsiran combination studies led by Vir Biotechnology.\u00a0Key data readouts will be shared in the coming months at scientific conferences throughout 2025.<\/p>\n<p> <b>About Hepatitis B <\/b> <\/p>\n<p>Hepatitis B virus (HBV) infection is one of the world&#8217;s most significant infectious disease threats with more than 254 million people infected globally.<sup>[1]<\/sup> Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.<sup>[1]<\/sup>\u00a0HBV is of exceptional concern in China, where 87 million people are chronically infected.<sup>[2]<\/sup><\/p>\n<p> <b>About BRII-179<\/b> <\/p>\n<p>BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the &#8220;CDE&#8221;) of the National Medical Products Administration (the &#8220;NMPA&#8221;) granted BRII-179 Breakthrough Therapy Designation.<\/p>\n<p> <b>About Elebsiran (previously known as BRII-835, VIR-2218)<\/b> <\/p>\n<p>Elebsiran is an investigational subcutaneously\u00a0administered HBV-targeting siRNA designed to degrade hepatitis B virus RNA transcripts and\u00a0limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral\u00a0activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization\u00a0Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially\u00a0can result in an increased therapeutic index. Brii Bio\u00a0licensed exclusive rights to develop and\u00a0commercialize elebsiran for the\u00a0Greater China territory from Vir Biotechnology, Inc. in 2020.<\/p>\n<p> <b>About Brii Bio<\/b> <\/p>\n<p>Brii Biosciences Limited (&#8220;Brii Bio&#8221;, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit <a href=\"http:\/\/www.briibio.com\/\" target=\"_blank\" rel=\"nofollow\">www.briibio.com<\/a>.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"> <span class=\"prnews_span\">[1]\u00a0World Health Organization. (April\u00a02024). <i>Global hepatitis report 2024: action for access in low- and middle-income countries<\/i><i>.<\/i>\u00a0World Health Organization. Retrieved from https:\/\/www.who.int\/publications\/i\/item\/9789240091672<\/span> <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"> <span class=\"prnews_span\">[2] World Health Organization. <i>Hepatitis.<\/i> World Health Organization. Retrieved from https:\/\/www.who.int\/china\/health-topics\/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.<\/span> <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1690538\/Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li> <i>End of treatment (EOT) data from Cohort 4 of the\u00a0ENSURE\u00a0study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 <\/i> <i>na\u00efve participants<\/i> <i>, strengthening the case for a novel\u00a0enrichment strategy, utilizing\u00a0BRII-179 to\u00a0identify\u00a0and prime patients for improved functional cure outcomes<\/i> <\/li>\n<li> <i>24 Week follow-up results from Cohorts 1-3 of the ENSURE study demonstrated sustained off-treatment benefits of elebsiran + PEG-IFN\u03b1 combination<\/i> <i>therapy vs PEG-IFN\u03b1 alone<\/i> <\/li>\n<\/ul>\n<p> <span class=\"legendSpanClass\">DURHAM, N.C. and BEIJING<\/span>, <span class=\"legendSpanClass\">May 8, 2025<\/span> \/PRNewswire\/ &#8212; <a href=\"http:\/\/www.briibio.com\/\" target=\"_blank\" rel=\"nofollow\">Brii Biosciences Limited<\/a> (&#8220;Brii Bio&#8221; or the &#8220;Company&#8221;, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced data from its ongoing Phase 2 ENSURE study\u00a0as late-breaking posters at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, the Netherlands.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>ENSURE (NCT05970289) is a multicenter, open-label\u00a0Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to the combination treatment with pegylated interferon alpha (PEG-IFN\u03b1) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU\/mL.<\/p>\n<p>Cohort 4 enrolled participants who completed 9 doses of BRII-179, a recombinant protein-based therapeutic vaccine,\u00a0in combination with elebsiran in a previous APAC study BRII-179-835-001 (NCT04749368) to receive elebsiran and PEG-IFN\u03b1 combination treatment. These participants were grouped based on their anti-HBs response induced by prior BRII-179 treatment: those with peak anti-HBs titers \u2265 10 IU\/L are defined as anti-HBs responders, and those with peak anti-HBs titers &lt; 10 IU\/L as non-responders. The design of Cohort 4 as part of this study was based on the insight that BRII-179 could differentiate between immune responders and non-responders, offering the potential to predict future response to therapy.<\/p>\n<p>Interim\u00a0data\u00a0from\u00a0Cohort 4 showed that anti-HBs responders achieved a substantially higher rate of HBsAg seroclearance than non-responders.\u00a0At EOT (Week 48), 61% (11\/18) of anti-HBs responders achieved HBsAg seroclearance, compared to 10% (1\/10) of non-responders. Among the 11 anti-HBs responders who achieved HBsAg loss, 91% (10\/11) had anti-HBs titers \u2265 100 IU\/L at EOT.<\/p>\n<p>Of note, BRII-179 experienced participants in Cohort 4 achieved HBsAg loss faster than BRII-179 na\u00efve\u00a0participants in Cohort 2 and 3. 83% (10\/12) of HBsAg loss in BRII-179 experienced participants occurred by Week 24, compared to 55% (6\/11) in BRII-179 na\u00efve participants. These findings suggest rapid HBsAg seroclearance in subjects with higher anti-HBs titers may translate into durable HBsAg loss and the potential to evaluate shorter treatment durations of PEG-IFN\u03b1.<\/p>\n<p>Additional data from Cohorts 1-3 of the ENSURE study showed the combination therapy of elebsiran either 100 mg or 200 mg and PEG-IFN\u03b1 resulted in higher HBsAg loss rate at 24 weeks post EOT compared to PEG-IFN\u03b1 alone, supporting the additive benefit of siRNA.<\/p>\n<p>&#8220;The data from Cohort 4 of the ENSURE study are encouraging. We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in\u00a0achieving\u00a0a higher HBsAg seroclearance rate,&#8221; said David Margolis, MD, Chief Medical Officer of Brii Bio. &#8220;With BRII-179, we may identify patients with less impaired intrinsic immunity and further prime their immune response. This approach may provide more durable HBsAg loss and potentially shorter treatment duration of PEG-IFN\u03b1. We are moving full speed ahead with our clinical efforts to deliver a meaningful option to the chronic hepatitis B patients long left waiting.&#8221;<\/p>\n<p> <b>Abstract Number:\u00a0<\/b>LB25123\/ LBP-018<\/p>\n<p> <b>Title:\u00a0<\/b>Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved faster and higher rate of hepatitis B virus surface antigen seroclearance on elebsiran plus pegylated interferon-alfa: end of treatment data from ENSURE study<\/p>\n<p> <b>Presenter:<\/b>\u00a0Grace Lai-Hung Wong, MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine), Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics\u00a0in Hong Kong SAR, China<\/p>\n<ul type=\"disc\">\n<li>A total of 28 participants with baseline\u00a0HBsAg &gt; 100 and \u2264 3000 IU\/mL were analyzed. 18 and 10 participants had peak anti-HBs titer \u2265 10 IU\/L (defined as anti-HBs responders) and &lt; 10 IU\/L (defined as non-responders) induced by BRII-179 in the previous study, respectively.<\/li>\n<li>Median [range]\u00a0HBsAg at the time of initiating elebsiran + PEG-IFN\u03b1 was numerically higher in anti-HBs responders (539.4 [106.7-2165.0] IU\/mL) than in non-responders (219.3 [106.7-671.5] IU\/mL). At EOT (Week 48), 61% (11\/18) of anti-HBs responders achieved HBsAg seroclearance, compared to 10% (1\/10) of non-responders.<\/li>\n<li>Among the\u00a0anti-HBs responders who lost HBsAg, 91% (10\/11) had anti-HBs titers \u2265 100 IU\/L at EOT.<\/li>\n<li>BRII-179 experienced participants achieved\u00a0HBsAg loss faster than BRII-179 na\u00efve participants, with 83% (10\/12) of HBsAg loss occurring by Week 24 (vs 55% [6\/11] in BRII-179 na\u00efve participants).<\/li>\n<li>Elebsiran + PEG-IFN\u03b1 was generally safe and tolerated in BRII-179 experienced participants.<\/li>\n<\/ul>\n<p> <b>Abstract Number:\u00a0<\/b>LB25115\/ LBP-016<br \/><b>Title: <\/b>Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study<br \/><b>Presenter:<\/b>\u00a0David Margolis, MD, MPH, Chief Medical Officer of Brii Biosciences<\/p>\n<ul type=\"disc\">\n<li>At Week 72 (24 weeks post\u00a0EOT), higher HBsAg loss rate was observed in participants on combination therapy of either elebsiran 200mg or 100 mg and PEG-IFN\u03b1 compared to PEG-IFN\u03b1 alone (21.1% [4\/19] or 33.3% [6\/18] vs 5.6% [1\/18]). \u00a0All the 11 participants with HBsAg loss had baseline HBsAg &lt; 1500 IU\/mL.<\/li>\n<li>Incidence of treatment emergent adverse events (TEAEs) was comparable between combination therapy cohorts and PEG-IFN\u03b1 alone cohort. Most TEAEs were consistent with known side effects of PEG-IFN\u03b1.<\/li>\n<\/ul>\n<p>As part of Brii Bio&#8217;s unique approach to developing a functional cure for HBV, the Company and its partners are actively progressing multiple combination studies with our differentiated portfolio, including\u00a0BRII-179 being evaluated in multiple combination studies with elebsiran led by Brii Bio; elebsiran being evaluated in combination with PEG-IFN\u03b1 in studies led by Brii Bio;\u00a0and tobevibart, an investigational broadly neutralizing monoclonal antibody targeting HBV, being evaluated in multiple Phase 2 and 3 tobevibart and elebsiran combination studies led by Vir Biotechnology.\u00a0Key data readouts will be shared in the coming months at scientific conferences throughout 2025.<\/p>\n<p> <b>About Hepatitis B <\/b> <\/p>\n<p>Hepatitis B virus (HBV) infection is one of the world&#8217;s most significant infectious disease threats with more than 254 million people infected globally.<sup>[1]<\/sup> Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.<sup>[1]<\/sup>\u00a0HBV is of exceptional concern in China, where 87 million people are chronically infected.<sup>[2]<\/sup><\/p>\n<p> <b>About BRII-179<\/b> <\/p>\n<p>BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the &#8220;CDE&#8221;) of the National Medical Products Administration (the &#8220;NMPA&#8221;) granted BRII-179 Breakthrough Therapy Designation.<\/p>\n<p> <b>About Elebsiran (previously known as BRII-835, VIR-2218)<\/b> <\/p>\n<p>Elebsiran is an investigational subcutaneously\u00a0administered HBV-targeting siRNA designed to degrade hepatitis B virus RNA transcripts and\u00a0limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral\u00a0activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization\u00a0Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially\u00a0can result in an increased therapeutic index. Brii Bio\u00a0licensed exclusive rights to develop and\u00a0commercialize elebsiran for the\u00a0Greater China territory from Vir Biotechnology, Inc. in 2020.<\/p>\n<p> <b>About Brii Bio<\/b> <\/p>\n<p>Brii Biosciences Limited (&#8220;Brii Bio&#8221;, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit <a href=\"http:\/\/www.briibio.com\/\" target=\"_blank\" rel=\"nofollow\">www.briibio.com<\/a>.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"> <span class=\"prnews_span\">[1]\u00a0World Health Organization. (April\u00a02024). <i>Global hepatitis report 2024: action for access in low- and middle-income countries<\/i><i>.<\/i>\u00a0World Health Organization. Retrieved from https:\/\/www.who.int\/publications\/i\/item\/9789240091672<\/span> <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"> <span class=\"prnews_span\">[2] World Health Organization. <i>Hepatitis.<\/i> World Health Organization. Retrieved from https:\/\/www.who.int\/china\/health-topics\/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.<\/span> <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-22506","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/22506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22506"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/22506\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}